Can we improve the treatment of congestion in heart failure?

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 9, 2011, Pages 1369-1379

  Metra, Marco ^a   Bugatti, Silvia ^a   Bettari, Luca ^a   Carubelli, Valentina ^a   Danesi, Rossella ^a   Lazzarini, Valentina ^a   Lombardi, Carlo ^a   Cas, Livio Dei ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

Author keywords

Acute heart failure; congestion; diuretics

Indexed keywords

ADENOSINE RECEPTOR BLOCKING AGENT; BUMETANIDE; DOPAMINE; ETACRYNIC ACID; FUROSEMIDE; INOTROPIC AGENT; LOOP DIURETIC AGENT; NATRIURETIC PEPTIDE RECEPTOR A; RELAXIN; ROLOFYLLINE; THIAZIDE DIURETIC AGENT; TORASEMIDE; VASOPRESSIN; VASOPRESSIN ANTAGONIST;

ACUTE HEART FAILURE; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; ELECTROLYTE DISTURBANCE; FLUID RETENTION; HOSPITAL DISCHARGE; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; KIDNEY FUNCTION; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TREATMENT OUTCOME; ULTRAFILTRATION;

ANIMALS; DIURETICS; DYSPNEA; EDEMA; FUROSEMIDE; HEART FAILURE; HUMANS; LUNG;

EID: 79956160272     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2011.557069     Document Type: Review

References (88)

1. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;12:933-89
2. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:e391-479
3. Publication Committee for the VMAC Investigators (Vasodilatation in the Management oacknerf Acute CHF). Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial. JAMA 2002;287:1531-40
4. Gheorghiade M, Konstam MA, Burnett JC Jr, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297:1332-43 (Pubitemid 46513234)
5. McMurray JJ, Teerlink JR, Cotter G, et al. Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 2007;298:2009-19 (Pubitemid 350074798)
6. Cleland JG, Freemantle N, Coletta AP, Clark AL. Clinical trials update from the American Heart Association: REPAIR-AMI, ASTAMI, JELIS, MEGA, REVIVE-II, SURVIVE, and PROACTIVE. Eur J Heart Fail 2006;8:105-10 (Pubitemid 43012109)
7. Gattis WA, O'Connor CM, Gallup DS, et al. Predischarge initiation of carvedilol in patients hospitalized for decompensated heart failure: results of the initiation management predischarge: process for assessment of carvedilol therapy in heart failure (IMPACT-HF) trial. J Am Coll Cardiol 2004;43:1534-41 (Pubitemid 38561330)
8. Yancy CW, Lopatin M, Stevenson LW, et al. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the Acute Decompensated Heart Failure National Registry (ADHERE) Database. J Am Coll Cardiol 2006;47:76-84 (Pubitemid 43005168)
9. Metra M, Cleland JG, Davison Weatherley B, et al. Dyspnoea in patients with acute heart failure. An analysis of its clinical course, determinants and relationship to 60 day outcomes in the PROTECT Pilot Study. Eur J Heart Fail 2010;12:499-507
10. Mebazaa A, Pang PS, Tavares M, et al. The impact of early standard therapy on dyspnoea in patients with acute heart failure: the URGENT-dyspnoea study. Eur Heart J 2010;31:832-41
11. Metra M, Teerlink JR, Felker GM, et al. Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study. Eur J Heart Fail 2010;12:1130-9
12. Fonarow GC, Peacock WF, Phillips CO, et al. Admission B-type natriuretic peptide levels and in-hospital mortality in acute decompensated heart failure. J Am Coll Cardiol 2007;49:1943-50 (Pubitemid 46694287)
13. O'Connor CM, Stough WG, Gallup DS, et al. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry. J Card Fail 2005;11:200-5 (Pubitemid 40462423)
14. Tavazzi L, Maggioni AP, Lucci D, et al. Nationwide survey on acute heart failure in cardiology ward services in Italy. Eur Heart J 2006;27:1207-15
15. Metra M, Ponikowski P, Dickstein K, et al. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail 2007;9:684-94 (Pubitemid 46705572)
16. Gheorghiade M, Abraham WT, Albert NM, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA 2006;296:2217-26 (Pubitemid 44708052)
17. Harjola VP, Follath F, Nieminen MS, et al. Characteristics, outcomes, and predictors of mortality at 3 months and 1 year in patients hospitalized for acute heart failure. Eur J Heart Fail 2010;12:239-48
18. Zannad F, Mebazaa A, Juilliere Y, et al. Clinical profile, contemporary management and one-year mortality in patients with severe acute heart failure syndromes: The EFICA study. Eur J Heart Fail 2006;8:697-705 (Pubitemid 44754746)
19. Metra M, Felker GM, Zaca V, et al. Acute heart failure: Multiple clinical profiles and mechanisms require tailored therapy. Int J Cardiol 2010;144:175-9
20. Gheorghiade M, Follath F, Ponikowski P, et al. Assessing and grading congestion in acute heart failure: a scientific statement from the acute heart failure committee of the heart failure association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 2010;12:423-33
21. Massie BM, O'Connor C, Metra M, et al. Efficacy and safety of rolofylline, an adenosine A1 - receptor antagonist in acute heart failure. N Engl J Med 2010;363:1419-28
22. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre- RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet. 2009;373:1429-39
23. Allen LA, Metra M, Milo-Cotter O, et al. Improvements in signs and symptoms during hospitalization for acute heart failure Follow different patterns and depend on the measurement scales used: an international, prospective registry to evaluate the evolution of measures of disease severity in acute heart failure (MEASURE-AHF). J Card Fail 2008;14:777-84
24. Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol 2009;53:557-73
25. Cotter G, Metra M, Milo-Cotter O, et al. Fluid overload in acute heartfailure-re-distribution and other mechanisms beyond fluid accumulation. Eur J Heart Fail 2008;10:165-9 (Pubitemid 351222743)
26. Adamson PB, Magalski A, Braunschweig F, et al. Ongoing right ventricular hemodynamics in heart failure: clinical value of measurements derived from an implantable monitoring system. J Am Coll Cardiol 2003;41:565-71 (Pubitemid 36223320)
27. Chaudhry SI, Wang Y, Concato J, et al. Patterns of weight change preceding hospitalization for heart failure. Circulation 2007;116:1549-54 (Pubitemid 47511418)
28. Jaarsma T, van Veldhuisen DJ. When, how and where should we 'coach' patients with heart failure: the COACH results in perspective. Eur J Heart Fail 2008;10:331-3
29. Stevenson LW, Zile M, Bennett TD, et al. Chronic ambulatory intracardiac pressures and future heart failure events. Circ Heart Fail 2010;3:580-7
30. Inglis SC, Clark RA, McAlister FA, et al. Structured telephone support or telemonitoring programmes for patients with chronic heart failure. Cochrane Database Syst Rev 2010;8:CD007228
31. Blair JE, Khan S, Konstam MA, et al. Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. Eur Heart J 2009;30:1666-73
32. Metra M, Gheorghiade M, Bonow RO, Dei Cas L. Post-discharge assessment after a heart failure hospitalization: the next step forward. Circulation 2010; In press
33. Solomon SD, Dobson J, Pocock S, et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007;116:1482-7 (Pubitemid 47480639)
34. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J 2007;154:260-6 (Pubitemid 47079017)
35. Hernandez AF, Greiner MA, Fonarow GC, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA 2010;303:1716-22
36. Lee DS, Stukel TA, Austin PC, et al. Improved outcomes with early collaborative care of ambulatory heart failure patients discharged from the emergency department. Circulation 2010; In press
37. Francis GS, Benedict C, Johnstone DE, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9 (Pubitemid 20367975)
38. Vallon V, Miracle C, Thomson S. Adenosine and kidney function: potential implications in patients with heart failure. Eur J Heart Fail 2008;10:176-87
39. Cooper HA, Dries DL, Davis CE, et al. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999;100:1311-15 (Pubitemid 29440124)
40. Domanski M, Norman J, Pitt B, et al. Studies of Left Ventricular Dysfunction. Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003;42:705-8 (Pubitemid 37000189)
41. Knight EL, Glynn RJ, McIntyre KM, et al. Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: results from the studies of left ventricular dysfunction (SOLVD). Am Heart J 1999;138:849-55 (Pubitemid 29523271)
42. Ahmed A, Husain A, Love TE, et al. Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J 2006;27:1431-9 (Pubitemid 43998077)
43. Domanski M, Tian X, Haigney M, Pitt B. Diuretic use, progressive heart failure, and death in patients in the DIG study. J Card Fail 2006;12:327-32 (Pubitemid 43817590)
44. Ahmed A, Young JB, Love TE, et al. A propensity-matched study of the effects of chronic diuretic therapy on mortality and hospitalization in older adults with heart failure. Int J Cardiol 2008;125:246-53 (Pubitemid 351400220)
45. Neuberg GW, Miller AB, O'Connor CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31-8 (Pubitemid 34734752)
46. Eshaghian S, Horwich TB, Fonarow GC. Relation of loop diuretic dose to mortality in advanced heart failure. Am J Cardiol 2006;97:1759-64 (Pubitemid 43817867)
47. Mielniczuk LM, Tsang SW, Desai AS, et al. The association between high-dose diuretics and clinical stability in ambulatory chronic heart failure patients. J Card Fail 2008;14:388-93 (Pubitemid 351749839)
48. Abdel-Qadir HM, Tu JV, Yun L, et al. Diuretic dose and long-term outcomes in elderly patients with heart failure after hospitalization. Am Heart J 2010;160:264-71
49. Hasselblad V, Gattis Stough W, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007;9:1064-9 (Pubitemid 47451811)
50. Peacock WF, Costanzo MR, De Marco T, et al. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology 2009;113:12-19
51. Levy WC, Mozaffarian D, Linker DT, et al. The seattle heart failure model: prediction of survival in heart failure. Circulation 2006;113:1424-33 (Pubitemid 43739439)
52. Butler J, Forman DE, Abraham WT, et al. Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004;147:331-8 (Pubitemid 38176835)
53. Metra M, Nodari S, Parrinello G, et al. Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail 2008;10:188-95 (Pubitemid 351221392)
54. Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail 2007;13:599-608 (Pubitemid 47513536)
55. Felker GM, O'Connor CM, Braunwald E.; Heart Failure Clinical Research Network Investigators. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil? Circ Heart Fail 2009;2:56-62
56. Cleland JG, Coletta AP, Buga L, et al. Clinical trials update from the American College of Cardiology meeting 2010: DOSE, ASPIRE, CONNECT, STICH, STOP-AF, CABANA, RACE II, EVEREST II, ACCORD, and NAVIGATOR. Eur J Heart Fail 2010;12:623-9
57. Paterna S, Di Pasquale P, Parrinello G, et al. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as a bolus, in refractory congestive heart failure. Eur J Heart Fail 2000;2:305-13
58. Paterna S, Di Pasquale P, Parrinello G, et al. Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J Am Coll Cardiol 2005;45:1997-2003 (Pubitemid 40814121)
59. Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001;96:132-43 (Pubitemid 34114123)
60. Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol 2010;56:1527-34
61. Leier CV, Dei Cas L, Metra M. Clinical relevance and management of the major electrolyte abnormalities in congestive heart failure: hyponatremia, hypokalemia, and hypomagnesemia. Am Heart J 1994;128:564-74 (Pubitemid 24298312)
62. Anand IS, Ferrari R, Kalra GS, et al. Edema of cardiac origin. Studies of body water and sodium, renal function, hemodynamic indexes, and plasma hormones in untreated congestive cardiac failure. Circulation 1989;80:299-305 (Pubitemid 19195738)
63. Bayliss J, Norell M, Canepa-Anson R, et al. Untreated heart failure: clinical and neuroendocrine effects of introducing diuretics. Br Heart J 1987;57:17-22 (Pubitemid 17216948)
64. Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985;103:1-6 (Pubitemid 15068490)
65. McCurley JM, Hanlon SU, Wei SK, et al. Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004;44:1301-7 (Pubitemid 39208889)
66. Guazzi MD, Agostoni P, Perego B, et al. Apparent paradox of neurohumoral axis inhibition after body fluid volume depletion in patients with chronic congestive heart failure and water retention. Br Heart J 1994;72:534-9 (Pubitemid 24375746)
67. Marenzi G, Grazi S, Giraldi F, et al. Interrelation of humoral factors, hemodynamics, and fluid and salt metabolism in congestive heart failure: effects of extracorporeal ultrafiltration. Am J Med 1993;94:49-56 (Pubitemid 23021171)
68. Cotter OM, Sasimangalam AN, Arumugham PS, et al. Diuretics - a panacea for acute heart failure? Different formulations, doses, and combinations. Heart Fail Monit 2008;6:9-19
69. Friedel HA, Buckley MM. Torasemide. A review of its pharmacological properties and therapeutic potential. Drugs 1991;41:81-103 (Pubitemid 21920728)
70. Cosín J, Díez J.; TORIC investigators. Torasemide in chronic heart failure: results of the TORIC study. Eur J Heart Fail 2002;4:507-13 (Pubitemid 36564972)
71. Maskin CS, Ocken S, Chadwick B, LeJemtel TH. Comparative systemic and renal effects of dopamine and angiotensin-converting enzyme inhibition with enalaprilat in patients with heart failure. Circulation 1985;72:846-52 (Pubitemid 16245196)
72. Elkayam U, Ng TM, Hatamizadeh P, et al. Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation 2008;117:200-5
73. Friedrich JO, Adhikari N, Herridge MS, Beyene J. Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. Ann Intern Med 2005;142:510-24
74. Kellum JA, M Decker J. Use of dopamine in acute renal failure: a meta-analysis. Crit Care Med 2001;29:1526-31 (Pubitemid 32762331)
75. Mullens W, Abrahams Z, Skouri HN, et al. Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol 2008;51:300-6
76. Damman K, van Deursen VM, Navis G, et al. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol 2009;53:582-8
77. Zemljic G, Bunc M, Yazdanbakhsh AP, Vrtovec B. Levosimendan improves renal function in patients with advanced chronic heart failure awaiting cardiac transplantation. J Card Fail 2007;13:417-21 (Pubitemid 47176926)
78. Filippatos G, Parissis JT. Vasopressin antagonists for the treatment of acute decompensated heart failure: when, for whom, for how long, and on what standard therapy? J Card Fail 2008;14:648-50
79. Goldsmith SR, Brandimarte F, Gheorghiade M. Congestion as a therapeutic target in acute heart failure syndromes. Prog Cardiovasc Dis 2010;52:383-92
80. Konstam MA, Gheorghiade M, Burnett JC Jr, et al.; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-31 (Pubitemid 46513233)
81. Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure. J Am Coll Cardiol 2005;46:2043-6
82. Bourge RC, Tallaj JA. Ultrafiltration: a new approach toward mechanical diuresis in heart failure. J Am Coll Cardiol 2005;46:2052-3 (Pubitemid 41713591)
83. Bart BA. Treatment of congestion in congestive heart failure: ultrafiltration is the only rational initial treatment of volume overload in decompensated heart failure. Circ Heart Fail 2009;2:499-504
84. Costanzo MR, Guglin ME, Saltzberg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2003;49:675-83
85. Kittleson M, Hurwitz S, Shah MR, et al. Development of circulatory-renal limitations to angiotensin-converting enzyme inhibitors identifies patients with severe heart failure and early mortality. J Am Coll Cardiol 2003;41:2029-35 (Pubitemid 36677127)
86. Gottlieb SS. Adenosine A1 antagonists and the cardiorenal syndrome [Review] Curr Heart Fail Rep 2008;5(2):105-9
87. Cotter G, Dittrich HC, Weatherley BD, et al. The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008;14:631-40
88. Weatherley BD, Cotter G, Dittrich HC, et al. Design and rationale of the PROTECT study: a placebo-controlled randomized study of the selective A1 adenosine receptor antagonist rolofylline for patients hospitalized with acute decompensated heart failure and volume overload to assess treatment effect on congestion and renal function. J Card Fail 2010;16:25-35